Skip to Content
Merck
All Photos(3)

Key Documents

SAB5600047

Sigma-Aldrich

Anti-BRAF (V600E) antibody, Rabbit monoclonal

recombinant, expressed in HEK 293 cells, clone RM8, purified immunoglobulin

Synonym(s):

Anti-B-RAF1, Anti-B-raf, Anti-BRAF-1, Anti-BRAF1, Anti-NS7, Anti-RAFB1

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

recombinant

expressed in HEK 293 cells

Quality Level

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

RM8, monoclonal
recombinant monoclonal

form

buffered aqueous glycerol solution

species reactivity

human

concentration

~1 mg/mL

technique(s)

ELISA: 0.5-2 μg/mL
immunoblotting: 0.5-2 μg/mL
immunocytochemistry: 0.5-5 μg/mL
immunohistochemistry: 0.5-5 μg/mL

isotype

IgG

NCBI accession no.

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... BRAF(673)

General description

BRAF (B-Raf proto-oncogene) is a serine-threonine kinase, that codes for B-Raf protein. It is located on human chromosome 7q34.

Specificity

This antibody reacts to the BRAF V600E mutant. No cross reactivity with wild type BRAF.

Immunogen

Peptide corresponding to BRAF V600E mutant

Biochem/physiol Actions

BRAF (B-Raf proto-oncogene) participates in signaling direct cell growth. It induces tumor growth by initiating the mitogen-activated protein kinase (MAPK) pathway in various tumors like cutaneous melanoma and carcinomas of the thyroid and colon.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Solution in phosphate buffered saline containing 50% glycerol, 1% BSA and 0.09% sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Maria Russi et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 180, 106311-106311 (2022-10-24)
Two clinically approved anticancer drugs targeting BRAF in melanoma patients - dabrafenib (DAB) and vemurafenib (VEM) - have been successfully encapsulated into nanomicelles formed upon self-assembly of an amphiphilic dendrimer AD based on two C18 aliphatic chains and a G2
Daniel Delev et al.
Scientific reports, 10(1), 96-96 (2020-01-11)
Long-term epilepsy-associated tumors (LEATs) represent mostly benign brain tumors associated with drug-resistant epilepsy. The aim of the study was to investigate the specific transcriptional signatures of those tumors and characterize their underlying oncogenic drivers. A cluster analysis of 65 transcriptome
Xuhong Wang et al.
Oncology letters, 18(1), 927-935 (2019-07-11)
Keratin 19 (KRT19) is a type I cytokeratin that serves an important role in multiple types of cancer; however, little is known regarding its role in thyroid cancer. Therefore, the aim of the current study was to investigate the role
The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.
Hannan EJ, et al.
Medicine, 96(48), e8404-e8404 (2017)
Elin Schoultz et al.
Disease models & mechanisms, 15(2) (2021-08-12)
Cancer cells hijack developmental growth mechanisms but whether tissue morphogenesis and architecture modify tumorigenesis is unknown. Here, we characterized a new mouse model of sporadic thyroid carcinogenesis based on inducible expression of BRAF carrying a Val600 Glu (V600E) point mutation

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service